Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms

Applied Microbiology and Biotechnology
Carole NagantJean-Paul Dehaye

Abstract

The bactericidal activity of a cholic acid antimicrobial derivative, CSA-13, was tested against eight strains of Pseudomonas aeruginosa (both reference and clinical strains) and compared with the response to tobramycin. In planktonic cultures, the minimal inhibitory and minimal bactericidal concentrations of CSA-13 and tobramycin were in the 1-25 mg/L range except for one mucoid clinical strain which was much less sensitive to tobramycin (minimal bactericidal concentration, 65-125 mg/L). In young (24 h) biofilms, the sensitivity to CSA-13 was reduced (half-maximal concentration CSA-13 averaged 88 mg/L) and varied among the eight strains. The sensitivity to tobramycin was also very variable among the strains and some were fully resistant to the aminoglycoside. The combination of tobramycin with CSA-13 was synergistic in five strains. Only one strain showed antagonism between the two drugs at low concentrations of CSA-13. One reference and five clinical strains were tested in mature (12 days) biofilms. The effect of CSA-13 was delayed, some strains requiring 9 days exposure to the drug to observe a bactericidal effect. All the strains were tolerant to tobramycin but the addition of CSA-13 with tobramycin was synergistic in three ...Continue Reading

References

Dec 1, 1994·The Journal of Infectious Diseases·U RömlingB Tümmler
Jul 1, 1996·Journal of Bacteriology·A L Dela Vega, A H Delcour
Sep 7, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S K FridkinF C Tenover
Aug 19, 2000·Infection and Immunity·T R de Kievit, B H Iglewski
Aug 25, 2001·Journal of Endotoxin Research·J S Gunn
Nov 26, 2002·FEMS Microbiology Letters·Paul B SavageQunying Guan
Jun 6, 2003·Cellular and Molecular Life Sciences : CMLS·R Bals, J M Wilson
Jan 24, 2004·The European Respiratory Journal·R C Boucher
Apr 17, 2007·Respiration; International Review of Thoracic Diseases·Iwona StelmachWłodzimierz Stelmach
Jun 30, 2007·Biochimica Et Biophysica Acta·Raquel F EpandRichard M Epand
Feb 1, 2008·Pulmonary Pharmacology & Therapeutics·Sophie Moreau-MarquisGeorge A O'Toole
Mar 25, 2008·American Journal of Physiology. Lung Cellular and Molecular Physiology·Sophie Moreau-MarquisBruce A Stanton
Apr 3, 2008·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Kenneth L Rosenthal
Oct 7, 2008·Drug News & Perspectives·Richard M EpandPaul B Savage
Jan 24, 2009·Trends in Microbiology·Russell D Monds, George A O'Toole
Feb 26, 2009·Oral Microbiology and Immunology·E IsogaiP B Savage
Feb 27, 2009·FEMS Microbiology Reviews·W James Gooderham, Robert E W Hancock
May 7, 2009·Pediatric Pulmonology·Thomas BjarnsholtNiels Høiby
Feb 2, 2010·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Eduardo Guaní-GuerraLuis M Terán

❮ Previous
Next ❯

Citations

Oct 5, 2012·Clinical Microbiology Reviews·Lucía Fernández, Robert E W Hancock
Sep 13, 2011·Microbial Biotechnology·Mirian DomenechMiriam Moscoso
Feb 16, 2016·MedChemComm·Sylvie Garneau-Tsodikova, Kristin J Labby
Dec 23, 2020·Biofouling·Débora de Souza Collares Maia Castelo-BrancoJosé Júlio Costa Sidrim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.